Genprex Stock (NASDAQ:GNPX)

Ownership Financials Chart

Previous Close

$2.00

52W Range

$1.71 - $55.00

50D Avg

$2.21

200D Avg

$7.99

Market Cap

$3.20M

Avg Vol (3M)

$1.03M

Beta

-0.72

Div Yield

GNPX Company Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Mar 29, 2018

Website

GNPX Performance

GNPX Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	-	$-31.08M	$-23.83M
Net Income	$-21.39B	$-30.86M	$-29.46M
EBITDA	-	$-31.06M	$-23.81M
Basic EPS	$-5.34K	$-22.58	$-24.59
Diluted EPS	$-5.34K	$-22.56	$-24.58

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
LIMN	Liminatus Pharma, Inc. Class A Common Stock
GRI	GRI Bio, Inc.
BDRX	Biodexa Pharmaceuticals Plc
JAGX	Jaguar Health, Inc.
INM	InMed Pharmaceuticals Inc.
CNSP	CNS Pharmaceuticals, Inc.
CERO	CERo Therapeutics Holdings, Inc.
CMMB	Chemomab Therapeutics Ltd.
BIVI	BioVie Inc.